A new breast cancer survival gap baseline from the World Health Organization puts five-year net survival at a global median of 77.8% for women diagnosed between 2017 and 2021—and shows how sharply that figure splits by region and income. High-income countries reached a median of 87.3%. Low-income countries sat at 41.9%.
The July 8 departmental update is the first time WHO has published comparable five-year estimates for all 194 Member States. For the Health desk, the story is less about a single breakthrough therapy and more about whether health systems catch disease early and finish treatment.
Breast cancer survival gap by region and income
According to the WHO, regional medians ranged from 39.1% in the African Region to 88.5% in the Region of the Americas and 84.0% in Europe. Lower-middle-income countries reached 60.1%. Upper-middle-income countries reached 78.7%.
Breast cancer remains the most common cancer among women in 158 countries. In 2024 it caused about 694,000 deaths worldwide, with 70% in low- and middle-income countries. An estimated 8 million women—mostly in high-income countries—were living with the disease.
How WHO built the estimates
Researchers synthesized observed registry data from 67 of 194 Member States with covariates such as stage at diagnosis, access to cancer medicines, radiotherapy and mammography capacity, and adult mortality. Among 36 fragile and conflict-affected states, only two had observed survival data. That gap itself is part of the inequity story.
Stage at diagnosis was a key predictor. Countries that diagnose more advanced disease show lower long-term survival. The findings support the Global Breast Cancer Initiative pillars: diagnose 60% of invasive cancers at stage I or II; complete diagnosis within 60 days of presentation; and finish multimodality treatment for at least 80% of patients when indicated. The initiative aims to cut premature breast cancer mortality by 2.5% a year and save 2.5 million lives by 2040.
What the numbers mean for policy
Dr Alarcos Cieza of WHO said survival measures how well a system detects and treats breast cancer—early detection, timely diagnosis, multimodality treatment, and care quality. Axo’s analysis is that the breast cancer survival gap is a systems metric, not a verdict on individual patients.
Evidence caveats matter. Many countries lack population-based registries, so modeled estimates fill holes. Local stage mix, medicine stockouts, and conflict can move outcomes faster than national averages imply. The Nature Medicine paper and WHO consultation process give countries a transparent baseline to track, not a clinical prescription.
What comes next is operational: expand early detection pathways, shorten time to diagnosis, and secure treatment completion where capacity is thin. This report does not advise individuals on screening or therapy. It measures whether countries are closing a preventable survival divide.